Skip to Content
Merck
All Photos(1)

Documents

11484281001

Roche

BM Blue POD Substrate, soluble

solution (ready-to-use), suitable for ELISA, pkg of 100 mL

Synonym(s):

3,3′,5,5′-Tetramethylbenzidine solution

Sign Into View Organizational & Contract Pricing


About This Item

Empirical Formula (Hill Notation):
C16H20N2
CAS Number:
Molecular Weight:
240.34
Beilstein:
2808541
MDL number:
UNSPSC Code:
12352204
PubChem Substance ID:

description

3,3′-5,5′-Tetramethylbenzidine (TMB)

Quality Level

form

solution (ready-to-use)

mol wt

Mr 240.35

packaging

pkg of 100 mL

manufacturer/tradename

Roche

technique(s)

ELISA: suitable

solubility

water: soluble

storage temp.

2-8°C

SMILES string

Cc1cc(cc(C)c1N)-c2cc(C)c(N)c(C)c2

InChI

1S/C16H20N2/c1-9-5-13(6-10(2)15(9)17)14-7-11(3)16(18)12(4)8-14/h5-8H,17-18H2,1-4H3

InChI key

UAIUNKRWKOVEES-UHFFFAOYSA-N

Looking for similar products? Visit Product Comparison Guide

Application

BM Blue POD Substrate, soluble, is ideal for ELISA applications. It has been used in fluorescein-tagged exendin-4 binding assay.

Specifications

Formula: C16H20N2
Color: blue; yellow after reaction is stopped
Evaluation: photometric (450 nm)

Physical form

Solution, ready-to-use

Analysis Note

Absorption: Identical to TMB absorption spectrum

Other Notes

For life science research only. Not for use in diagnostic procedures.

Storage Class Code

12 - Non Combustible Liquids

WGK

WGK 1

Flash Point(F)

No data available

Flash Point(C)

No data available


Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Daming Zhou et al.
Nature structural & molecular biology, 27(10), 950-958 (2020-08-02)
The COVID-19 pandemic has had an unprecedented health and economic impact and there are currently no approved therapies. We have isolated an antibody, EY6A, from an individual convalescing from COVID-19 and have shown that it neutralizes SARS-CoV-2 and cross-reacts with
Kuan-Ying A Huang et al.
PLoS pathogens, 17(2), e1009352-e1009352 (2021-02-27)
Serological and plasmablast responses and plasmablast-derived IgG monoclonal antibodies (MAbs) have been analysed in three COVID-19 patients with different clinical severities. Potent humoral responses were detected within 3 weeks of onset of illness in all patients and the serological titre
Jiandong Huo et al.
Nature structural & molecular biology, 27(9), 846-854 (2020-07-15)
The SARS-CoV-2 virus is more transmissible than previous coronaviruses and causes a more serious illness than influenza. The SARS-CoV-2 receptor binding domain (RBD) of the spike protein binds to the human angiotensin-converting enzyme 2 (ACE2) receptor as a prelude to
Sindhu Rajan et al.
Molecular metabolism, 4(4), 265-276 (2015-04-02)
Glucagon-like peptide 1 (GLP-1) enhances insulin secretion and protects β-cell mass. Diabetes therapies targeting the GLP-1 receptor (GLP-1R), expressed in numerous tissues, have diminished dose-response in patients with type 2 diabetes compared with healthy human controls. The aim of this

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service